Bumetanide
Clinical data | |
---|---|
Trade names | Bumex, Burinex, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a684051 |
License data |
|
Pregnancy category |
|
intramuscular | |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Almost complete (~80%) |
Protein binding | 97% |
Metabolism | Liver |
Elimination half-life | ~0.8 hours |
Excretion | Kidney |
Identifiers | |
| |
JSmol) | |
| |
| |
(verify) |
Bumetanide, sold under the brand name Bumex among others, is a
Common side effects include dizziness,
Bumetanide was patented in 1968 and came into medical use in 1972.
Medical uses
It is used to treat
Side effects
Common side effects include dizziness,
Safety during pregnancy and breastfeeding is unclear.[3]
Pharmacology
Pharmacodynamics
Bumetanide is a loop diuretic and works by decreasing the reabsorption of sodium by the kidneys. The main difference between bumetanide and furosemide is in their
Synthesis
Bumetanide is synthesized from
Society and culture
It 2008, ESPN reported that four
Bumetanide was an undisclosed active ingredient in the over-the-counter weight loss supplement StarCaps, which was removed from the market after its presence was discovered by the United States Food and Drug Administration.[18]
Research
In the brain, bumetanide blocks the
The drug has also been studied as a treatment for
References
- FDA. Retrieved 22 Oct 2023.
- ^ a b c d e f g h i j k l m n o p "Bumetanide Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 8 April 2019.
- ^ a b "Bumetanide (Bumex) Use During Pregnancy". Drugs.com. Retrieved 8 April 2019.
- ^ ISBN 978-0-85711-338-2.
- ISBN 978-3-527-60749-5.
- hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- ^ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
- ^ "Bumetanide - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
- PMID 14573734.
- S2CID 21612858.
- S2CID 10908796.
- ^ ISBN 0-07-142280-3.
- ^ DE 1964504, Feit PW, "Arzneimittelzubereitung mit einem Gehalt an 3-Butylamino-4-phenoxy-5-sulfamyl-benzoesaeure und deren Salzen", issued 9 July 1970, assigned to Leo Pharma Products, Ltd.
- PMID 5117690.
- ^ US 3634583, Feit PW, "Pharmaceutical composition for the treatment of oedematous conditions and hypertension", issued 11 January 1972, assigned to Leo Pharmaceutical Products Ltd AS
- ^ US 4082851, Feit PW, Nielsen OB, Bruun H, Bretting CA, "Sulphonamides, compositions containing the same and methods for using the same in the treatment of hypertension or odemeas", issued 4 April 1978, assigned to Leo Pharmaceutical Products Ltd AS
- ^ "McAllister, Smith, Grant, Texans' Pittman among players testing positive". ESPN.com. ESPN. October 26, 2008. Retrieved June 6, 2017.
- ^ Food and Drug Administration Office of Criminal Investigations (March 26, 2014). "Pills Sold Throughout the United States Contained an Undisclosed Prescription Drug Banned By the National Football League". U.S. Department of Justice Press Release. United States Food and Drug Administration. Retrieved June 6, 2017.
- S2CID 22267675.
- PMID 32730977.
Recent trials have indicated positive effects of bumetanide in autism spectrum disorder (ASD).
- PMID 32066666.
External links
- "Bumetanide". Drug Information Portal. U.S. National Library of Medicine.